PEG-MGF vs Thymosin Alpha-1

Performance

Immune

Research Only

Research Only

The MGF E-peptide acts locally on muscle satellite (stem) cells, promoting their proliferation and delaying terminal differentiation, which expands the progenitor pool available for fusion into damaged myofibers. Receptor-blocking studies by Yang & Goldspink (2002) indicated that the E-peptide acts through a receptor distinct from the classical IGF-1R, although the exact receptor remains unconfirmed — this is one reason MGF is mechanistically separable from mature IGF-1 or IGF-1 LR3. Conjugation of polyethylene glycol to the peptide reduces renal clearance and proteolysis, extending plasma half-life from minutes (native MGF) to several hours.

Tα1 acts primarily on dendritic cells and T-cells via Toll-like receptor signaling — TLR9-MyD88-IRF7 driving type I interferon, and TLR2-MyD88-NF-κB driving IL-12, TNF-α, and IL-6. It promotes dendritic cell maturation, T-cell differentiation and thymic output, enhances NK cell cytotoxicity, upregulates MHC class I expression, and induces indoleamine 2,3-dioxygenase (IDO) to balance inflammation with tolerance. Unlike broad cytokine stimulators, Tα1 is a context-dependent immunomodulator that can enhance deficient responses and restrain overactive ones.

Several hours (pegylated) vs. minutes (native MGF); human PK not formally characterized

Approximately 2 hours after SubQ administration